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 INTRODUCTION 
 Opium is the air-dried extract of the opium poppy,  Papaver somni-
ferum . Th is extract includes a large number of molecules, including 
narcotic alkaloids (e.g., morphine and codeine), non-narcotic alka-
loids (e.g., papaverine, thebaine, and noscapine), and non-alkaloids 
(e.g., sugars and meconic acid) ( 1 ). Th ese compounds may aff ect 
human physiology and health in many diff erent ways, the totality of 
which could only be assessed in long-term human studies. 
 Opium has long been used for medical and recreational pur-
poses in many parts of the world, including Iran. Avicenna ’ s 
tenth century article was the main reference for medicinal use 
of opium until the nineteenth century ( 2 ). A combination of 
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 OBJECTIVES:  Opium use, particularly in low doses, is a common practice among adults in northeastern Iran. We 
aimed to investigate the association between opium use and subsequent mortality from disorders of 
the digestive tract. 
 METHODS:  We used data from the Golestan Cohort Study, a prospective cohort study in northeastern Iran, with 
detailed, validated data on opium use and several other exposures. A total of 50,045 adults were 
enrolled during a 4-year period (2004 – 2008) and followed annually until December 2012, with a 
follow-up success rate of 99 % . We used Cox proportional hazard regression models to evaluate the 
association between opium use and outcomes of interest. 
 RESULTS:  In all, 8,487 (17 % ) participants reported opium use, with a mean duration of 12.7 years. During the 
follow-up period 474 deaths from digestive diseases were reported (387 due to gastrointestinal cancers 
and 87 due to nonmalignant etiologies). Opium use was associated with an increased risk of death from 
any digestive disease (adjusted hazard ratio (HR)  =  1.55, 95 % confi dence interval (CI)  =  1.24 – 1.93). 
The association was dose dependent, with a HR of 2.21 (1.57 – 3.31) for the highest quintile of cumu-
lative opium use vs. no use ( P trend  =  0.037). The HRs (95 % CI) for the associations between opium use 
and malignant and nonmalignant causes of digestive mortality were 1.38 (1.07 – 1.76) and 2.60 (1.57 –
 4.31), respectively. Increased risks were seen both for smoking opium and for ingestion of opium. 
 CONCLUSIONS:  Long-term opium use, even in low doses, is associated with increased risk of death from both 
malignant and nonmalignant digestive diseases. 
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criminalization of opium use, as well as availability of other 
psychoactive drugs such as cannabis, has resulted in lower use of 
opium in the developed world. Yet opium is still commonly used in 
other parts of the world, mainly in Western and Central Asia ( 1 ). 
Globally, an estimated 13 – 22 million people, mostly from Asian 
countries, consumed opium and its derivatives in 2008 ( 3 ). 
 A popular belief among lay people, and even perhaps among 
the older generation of physicians in Western and Central Asia, 
is that long-term use of low-dose opium can prolong survival by 
preventing chronic diseases, such as diabetes mellitus, cardiovas-
cular diseases, and cancer. However, published data do not support 
this hypothesis. Several case – control studies and case series have 
suggested deleterious eff ects of opium consumption, associating its 
use with higher risk of cardiovascular outcomes and a variety of 
cancers ( 4 – 14 ). A recent report from the Golestan Cohort Study 
(GCS) showed that opium use, even in low doses, was associated 
with a near doubling of all-cause mortality ( 15 ). 
 Opiates are metabolized principally in the liver, and chronic 
ingestion of morphine in mice has been shown to cause his-
topathological changes in the liver resulting in abnormal liver 
function tests ( 16 ). In humans, long-term use of opiates, particu-
larly morphine, can commonly cause constipation, which results 
from opium ’ s disruption of neurotransmission in the enteric nerv-
ous system, leading to decreased motility and decreased secretion 
of water, electrolytes, and bile in the gastrointestinal (GI) tract ( 17 ). 
Th us, opium use may be involved in the etiology of multiple diges-
tive tract disorders. Several studies have reported an association 
between opium use and esophageal cancer ( 4,18,19 ) or gastric can-
cer ( 20,21 ), but no study has reported on the association between 
opium use and all digestive disease-related mortality, including 
deaths from diseases with nonmalignant etiologies. We conducted 
this study to investigate the association between opium use and 
mortality due to GI and liver diseases. 
 METHODS 
 Study population 
 Th e GCS is a prospective cohort study of 50,045 adults, aged 40 – 75 
years, from Golestan province of Iran who were recruited between 
January 2004 and June 2008. A detailed description of this study 
is available elsewhere ( 22,23 ). In summary, a total of 10,033 par-
ticipants were enrolled from Gonbad City, the largest city in the 
study area, with participation rates of approximately 70 % and 50 % 
for women and men, respectively. In addition, 40,012 participants 
were enrolled from 326 villages, with participation rates of 84 % 
for women and 70 % for men.  Figure 1 shows the fl ow chart of 
study recruitment. Seventy-fi ve percent of the study participants 
were Turkmen ethnics, who likely descended from Turkic tribes 
and migrated from the Altai Mountains on the border of China 
and Mongolia to northern Iran. Turkmens presently live in Turk-
menistan (part of the Ancient Iranian Empire) and northeastern 
Iran, primarily in Golestan province. 
 Opium use was assessed using a structured questionnaire, which 
included detailed questions about the age of starting opium use, 
daily amount, and frequency of use (how many days a week if 
weekly or more), routes of intake, opium types (teriak, sukhteh, 
shireh, and heroin) ( 15 ), and the age of quitting consumption, if 
the person had quit. If subjects used several types of opium, or they 
used opium intermittently (stopped and resumed use), data were 
recorded separately for each type and period of use. Th e accuracy 
of self-reported opium use in this population has been evaluated 
by comparing the presence of codeine or morphine in urine 
All eligible individuals aged 40 – 75 years in eastern Golestan province (N = 81,223 )
Alive* (N =46,603 )
28% did not accept
Other deaths (N =2,636 )
Died* (N =3,110 )
The Golestan cohort study participants (N =50,045 )
Randomly selected subjects who were invited to participate (N =69,720 )
Total GI deaths (N =474)
Non-malignant GI deaths (N =87 )
Malignant GI deaths (N =387 )
Lost to follow-up* (N =332 )
 Figure 1 .  The Golestan Cohort Study fl owchart of enrollment, and the outcome events through 17 December 2012 ( * ). GI, gastrointestinal. 
